BioCatalystWatch
ZLABWorkspace / ZLAB / OverviewCompany library
Price
Market cap
Next catalystInitiate first-line randomized Phase 3 in Q4 2026, by year-end, based on emerging dataZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3 · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

M1 muscarinic receptor × M4 muscarinic receptor × Peripheral muscarinic receptors

Approved

PreINDP1P2P3FilingApproved
Zocilurtatug pelitecan

DLL3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Zocilurtatug pelitecan

DLL3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

ZL-1503

IL-13 × IL-31Rα

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

ZL-1503

IL-13 × IL-31Rα

PreINDP1P2P3FilingApproved
Upcoming / outlook

ZL-6201

LRRC15

PreINDP1P2P3FilingApproved
ZL-1222

PD-1

PreINDP1P2P3FilingApproved
ZL-1311

T-cell engager

MUC17 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

Elegrobart

IGF-1R

PreINDP1P2P3FilingApproved
Zocilurtatug pelitecanZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3

DLL3

PreINDP1P2FilingApproved
Upcoming / outlook

Zocilurtatug pelitecan

DLL3

PreINDP1P2FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Zocilurtatug pelitecan

DLL3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Zocilurtatug pelitecanZocilurtatug pelitecan + PD-L1 inhibition — planned first-line ES-SCLC Phase 3

DLL3

PreINDP1P2FilingApproved
Upcoming / outlook

ZL-1503

IL-13 × IL-31Rα

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

ZL-1311

T-cell engager

MUC17 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

Zocilurtatug pelitecan

DLL3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

ZL-1503

IL-13 × IL-31Rα

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

Zocilurtatug pelitecan

DLL3

PreINDP1P2P3FilingApproved
ZL-1503

IL-13 × IL-31Rα

PreINDP1P2P3FilingApproved
Zocilurtatug pelitecan

DLL3

PreINDP1P2P3FilingApproved
Zocilurtatug pelitecan

DLL3

PreINDP1P2P3FilingApproved

Approved / commercial

efgartigimod (VYVGART)

FcRn

Approved

PreINDP1P2P3FilingApproved

HER2

Approved

PreINDP1P2P3FilingApproved

PARP1 × PARP2

Approved

PreINDP1P2P3FilingApproved

Tissue factor (TF)

Approved

PreINDP1P2P3FilingApproved

History / paused

FGFR2b

PreINDP1P2P3FilingApproved

IL-17A

PreINDP1P2P3FilingApproved

Mutant EGFR

PreINDP1P2P3FilingApproved

CLDN18.2

PreINDP1P2P3FilingApproved

PD-1

PreINDP1P2P3FilingApproved

CCR8

PreINDP1P2P3FilingApproved

Mutant EGFR

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ZLAB SEC archive